EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

GLP-1 receptor agonist use and overall survival among women with type 2 diabetes and breast cancer: a retrospective cohort study

Rebecca A Nelson iD, Ying-Chuen Lai iD, Sung H Kil iD, Hayley S Lee, Joanne Mortimer iD, Ping H Wang iD

The Oncologist · 2026

DOI: 10.1093/oncolo/oyag268 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift The Oncologist, 2026. Verfasst von Rebecca A Nelson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Computational and Quantitative Medicine, Beckman Research Institute, City of Hope, Duarte, CA, 91010, United States. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Breast Neoplasms, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ko Family Foundation, Allen and Lee Hwa Chao Research Fund, and Tseng Visiting Scholar Fellowship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diabetes and obesity are associated with worse prognosis in women with breast cancer. However, the impact of glucagon-like peptide-1 receptor agonists (GLP-1RA) on survival following breast cancer diagnosis remains unclear.

Methods

We conducted a single institution, propensity-score matched, retrospective, 2-year landmark study of women with type 2 diabetes (T2D) diagnosed with breast cancer at City of Hope (2009-2025). Patients were categorized based on post-diagnosis exposure to GLP-1RA. Patients were compared across exposure groups using t-tests for continuous variables, chi-square tests for categorical variables, multivariable Cox proportional hazards models for overall mortality risk, and Kaplan-Meier plots for survival time.

Results

In 226 matched pairs, there were 47 deaths (30 in unexposed patients and 17 in exposed patients). GLP-1RA exposure was associated with a significantly lower risk of overall mortality (HR = 0.51, 95% CI 0.28-0.93, P = .03) on multivariable analysis. A sensitivity analysis in stage I-III patients yielded similar results (HR = 0.45, 95% CI 0.23-0.85, P = .01). Kaplan-Meier survival analysis also showed an association between increased overall survival and GLP-1RA exposure (log-rank P = .02).

Conclusions

In this retrospective cohort of women with T2D and breast cancer, GLP-1RA use after diagnosis was associated with improved overall survival in T2D. These findings reflect all-cause mortality and do not distinguish between cancer-specific and non-cancer causes of death and should therefore be interpreted accordingly.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Breast NeoplasmsGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsHumansFemaleRetrospective StudiesMiddle AgedAgedPrognosis

Stichwörter der Autor:innen

breast neoplasmsdiabetes mellitusglucagon-like peptide-1 receptor agonistsmortality

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Computational and Quantitative Medicine, Beckman Research Institute, City of Hope, Duarte, CA, 91010, United States.
  • Department of Internal Medicine, National Taiwan University Hospital, Taipei City, 100229, Taiwan.
  • Department of Diabetes, Endocrinology, and Metabolism, City of Hope National Medical Center, Duarte, CA, 91010, United States.
  • Arthur Riggs Diabetes & Metabolism Research Institute, Beckman Research Institute, City of Hope, Duarte, CA, 91010, United States.
  • Department of Medical Oncology & Therapeutics Research, City of Hope National Medical Center, Duarte, CA, 91010, United States.

ORCID-Profile: Rebecca A Nelson, Ying-Chuen Lai, Sung H Kil, Joanne Mortimer, Ping H Wang

Förderung

  • Ko Family Foundation, Allen and Lee Hwa Chao Research Fund, and Tseng Visiting Scholar Fellowship

Zitieren

APA

Nelson, R. A., Lai, Y. C., Kil, S. H., Lee, H. S., Mortimer, J., & Wang, P. H. (2026). GLP-1 receptor agonist use and overall survival among women with type 2 diabetes and breast cancer: a retrospective cohort study. The Oncologist. https://doi.org/10.1093/oncolo/oyag268

Vancouver

Nelson RA, Lai YC, Kil SH, Lee HS, Mortimer J, Wang PH. GLP-1 receptor agonist use and overall survival among women with type 2 diabetes and breast cancer: a retrospective cohort study. The Oncologist. 2026. doi:10.1093/oncolo/oyag268

BibTeX
@article{Nelson2026,
  author = {Nelson, Rebecca A and Lai, Ying-Chuen and Kil, Sung H and Lee, Hayley S and Mortimer, Joanne and Wang, Ping H},
  title = {GLP-1 receptor agonist use and overall survival among women with type 2 diabetes and breast cancer: a retrospective cohort study},
  journal = {The Oncologist},
  year = {2026},
  doi = {10.1093/oncolo/oyag268}
}
Kostenlos starten →